Related Content
- New alliance will crack down on adulterated products touting dietary supplement claims
- FDA opens dialogue of incorporating technology, pharmacy into switch paradigm
- FDA, parent agency HHS divided over emergency contraceptive prescription status
- FDA looks to simplify drug info packets
- K-V: FDA will approve Gestiva by PDUFA date
CHARLESTON, S.C. — The Food and Drug Administration has approved a treatment for a disease that causes brittle nails.
Innocutis announced the FDA approval of Nuvail (poly-ureaurethane) nail solution in the 16% strength. The drug is used to treat nail dystrophy, which causes fragile and brittle nails that crack and split.
One of the most common forms of nail dystrophy is brittle nail syndrome, which affects about 20% of the population, with women disproportionately affected. Patients with the condition report that their nails are painful and impair daily activities.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
